ľ¹Ï¸£ÀûÓ°ÊÓ

 works on the development and implementation of novel Mass Spectrometry (MS) based proteomics technologies to study protein regulation of biological processes, with the emphasis on neurological and cancer signaling. He develops and implements novel proteomics technology to study the molecular players involved in brain development and melanoma drug resistance. For this he comprehensively target the proteome on the level of post-translational modifications, protein expression and protein-protein interactions dynamics, through novel protein (complex) enrichment and top-down MS using our recently published dual fragmentation technology.